Phosphoramidite Market Report 2025

The phosphoramidite market size has grown strongly in recent years. It will grow from $1.01 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increasing demand for DNA and RNA synthesis, rising adoption of mRNA-based therapeutics, rising prevalence of genetic disorders, growing demand for synthetic biology, and growing investments in genomic research.

The phosphoramidite market size is expected to see strong growth in the next few years. It will grow to $1.4 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing utilization of phosphoramidites, rising demand for custom DNA and RNA synthesis, growing need for high-purity phosphoramidites, growing focus on personalized medicine, and rising biopharmaceutical companies. Major trends in the forecast period include synthetic biology expansion, development of novel phosphoramidite chemistries, advancements in genomic technologies, development activities in biotechnology, and development of personalized medicine.

The forecast of 7% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt oligonucleotide therapeutics by increasing costs of nucleic acid synthesis reagents (phosphoramidites) sourced from South Korea and Switzerland, thereby raising gene therapy development costs by 15-20% and delaying clinical trials for genetic disorders. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the biopharmaceutical sector is expected to drive the expansion of the phosphoramidite market in the future. The biopharmaceutical sector encompasses industries involved in the research, development, production, and commercialization of biologically-derived medical products such as vaccines, gene therapies, monoclonal antibodies, and recombinant proteins. This sector's growth is fueled by advances in biotechnology, a rise in chronic diseases, and increasing investments in research and development. Breakthroughs in biotechnology, including gene editing and monoclonal antibody therapies, have enabled more precise and effective treatments. As the biopharmaceutical sector grows, so does the demand for phosphoramidites, which play a vital role in synthesizing DNA and RNA for gene therapies, mRNA vaccines, and oligonucleotide-based drugs. As these therapies become more widely adopted, the need for phosphoramidites to create synthetic nucleic acids will rise, increasing their use in biopharmaceutical research and production. For example, according to the UK government, the core biopharmaceutical sector generated £46.7 billion ($58.4 billion) in revenue in 2022, accounting for 43% of the life sciences industry's total turnover. Additionally, the sector supports over 126,000 jobs and has seen substantial growth in research and development investments. As such, the expansion of the biopharmaceutical sector is driving the phosphoramidite market's growth.

Companies in the phosphoramidite market are focusing on enhancing DNA synthesis technologies to improve accuracy, speed, and sustainability while reducing hazardous waste. DNA synthesis involves creating DNA sequences using enzymes instead of chemical reagents, offering higher precision, speed, and sustainability. For example, in April 2022, Ansa Biotechnologies Inc., a US-based biotechnology firm, closed an oversubscribed $68 million Series A financing round led by Northpond Ventures, with participation from new and existing investors. This funding is intended to accelerate the development of Ansa's next-generation enzymatic DNA synthesis technology, also known as phosphoramidite synthesis, expand its R&D and manufacturing capabilities, and launch a customizable DNA synthesis service. A spinout from the University of California, Berkeley, Ansa uses a patented method to rapidly and accurately synthesize long DNA sequences, addressing current challenges in the industry.

In May 2023, Actylis, a US-based chemicals and raw materials company, formed a partnership with Innovassynth India to address vulnerabilities in the nucleic acid supply chain. This collaboration aims to strengthen the phosphoramidite market by ensuring a stable, transparent, and diversified supply chain, improving global access to high-quality nucleosides and phosphoramidites for pharmaceutical and biotech applications. Innovassynth India is a manufacturer of protected nucleosides, phosphoramidites, and reagents based in India.

Major players in the phosphoramidite market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Aragen Life Sciences, Twist Bioscience, Innovassynth Technologies (I) Ltd., Tokyo Chemical Industry Co. Ltd. (TCI), Aurigene Services, Eurofins Genomics, LGC Biosearch Technologies, Link Technologies Ltd., Creative Biolabs, Biosynth Carbosynth, TriLink BioTechnologies, ChemGenes Corporation, Berry & Associates Inc., Lumiprobe Corporation, Hongene Biotech Corporation, Carbolink India Pvt. Ltd., PolyOrg Inc., Glen Research, Gene Link Inc., emp BIOTECH GmbH.

North America was the largest region in the phosphoramidite market in 2024. Europe is expected to be the fastest-growing region during the forecast period. The regions covered in phosphoramidite report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the phosphoramidite market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phosphoramidite market consists of sales of spacer and linker phosphoramidites, fluorescent dye-Labeled phosphoramidites, biotinylated phosphoramidites, and structural phosphoramidites. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The phosphoramidite market research report is one of a series of new reports that provides phosphoramidite market statistics, including the phosphoramidite industry global market size, regional shares, competitors with the phosphoramidite market share, detailed phosphoramidite market segments, market trends, and opportunities, and any further data you may need to thrive in the phosphoramidite industry. This phosphoramidite market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Phosphoramidite is a chemical compound commonly used in the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) through solid-phase synthesis. It contains a phosphate group linked to an amine (-NR₂) and is highly reactive, enabling the stepwise addition of nucleotide bases in oligonucleotide synthesis. Phosphoramidites play a vital role in producing synthetic nucleic acids for various applications in research, diagnostics, and therapy.

The primary types of phosphoramidites include deoxyribonucleic acid (DNA) phosphoramidites, ribonucleic acid (RNA) phosphoramidites, labeled phosphoramidites, modifier phosphoramidites, and others. DNA phosphoramidites are chemical building blocks used in solid-phase DNA synthesis to create custom sequences for applications such as gene synthesis, PCR, and molecular diagnostics. Various synthesis methods, including the h-phosphonate method, phosphoramidite method, and trivalent phosphorus compounds method, are employed for applications such as gene synthesis, DNA sequencing, and DNA amplification. Phosphoramidites are widely used by end-users in academic research, the pharmaceutical industry, and the biotechnology sector.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.